Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Retained Earnings (2022 - 2025)

Historic Retained Earnings for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$2.0 billion.

  • Atara Biotherapeutics' Retained Earnings rose 114.61% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year increase of 114.61%. This contributed to the annual value of -$2.1 billion for FY2024, which is 433.7% down from last year.
  • According to the latest figures from Q3 2025, Atara Biotherapeutics' Retained Earnings is -$2.0 billion, which was up 114.61% from -$2.0 billion recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Retained Earnings ranged from a high of -$1.5 billion in Q2 2022 and a low of -$2.1 billion during Q4 2024
  • Moreover, its 4-year median value for Retained Earnings was -$2.0 billion (2023), whereas its average is -$1.9 billion.
  • As far as peak fluctuations go, Atara Biotherapeutics' Retained Earnings crashed by 1984.81% in 2023, and later skyrocketed by 114.61% in 2025.
  • Over the past 4 years, Atara Biotherapeutics' Retained Earnings (Quarter) stood at -$1.7 billion in 2022, then decreased by 16.31% to -$2.0 billion in 2023, then decreased by 4.34% to -$2.1 billion in 2024, then increased by 1.76% to -$2.0 billion in 2025.
  • Its Retained Earnings stands at -$2.0 billion for Q3 2025, versus -$2.0 billion for Q2 2025 and -$2.0 billion for Q1 2025.